Tier 2 — strong

The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis

Fatemeh Javadi, Shahryar Eghtesadi, Arman Ahmadzadeh, Naheed Aryaeian, Mozhdeh Zabihiyeganeh, Abbas Rahimi Foroushani, Shima Jazayeri
International journal of preventive medicine 2014 5(3):293-301

Bibliography

PubMed
PMID 24829713
PubMed Central
PMC4018638
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: None declared

Study snapshot

DesignRandomized double-blind placebo-controlled rheumatoid-arthritis trial
ModelHuman intervention research
Sample51 women
InterventionQuercetin 500 mg/day or placebo
Duration8 weeks
EndpointsBlood pressure; Inflammatory measures; Oxidative-stress measures

What the study showed, in plain terms

Published in 2014, this source examined inflammation and clinical symptoms. Design: Randomized double-blind placebo-controlled rheumatoid-arthritis trial. Sample/model: 51 women. The exposure or intervention was Quercetin 500 mg/day or placebo. Follow-up or treatment period: 8 weeks.

Oxidative-stress measures, CRP, and blood pressure did not differ significantly between groups.

Short small trial. It provides a null biomarker result that should be retained alongside symptom-focused reports from rheumatoid-arthritis research.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Oxidative-stress measures, CRP, and blood pressure did not differ significantly between groups.
  • The recorded outcome domains were Blood pressure; Inflammatory measures; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day or placebo; 8 weeks.

What this study can and cannot tell us

  • Short small trial. It provides a null biomarker result that should be retained alongside symptom-focused reports from rheumatoid-arthritis research.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology